Globus Medical Stock Pre-Market (+9.3%): Strong Prelim Q4 Sales & Upbeat 2026 Guidance
Globus Medical (GMED) is surging +9.3% pre-market after releasing impressive preliminary Q4 2025 sales figures and providing a robust forecast for 2026. The beat and raise has ignited bullish sentiment, but can the stock hold these gains and break out to new highs?
This is a structurally positive catalyst. The preliminary Q4 sales of $823.2 million significantly beat analyst estimates, representing a 25.2% year-over-year increase.
- Full-year 2025 sales are expected to be $2.936 billion, a 16.5% increase.
- Company issued strong 2026 revenue guidance of $3.18B – $3.22B, surpassing consensus.
- The core business, excluding recent acquisitions, showed solid 10.0% year-over-year growth.
But here is the interesting part. You are reading about this 9.3% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. High Quality Portfolio has flagged 5 new opportunities that haven not surged yet.
- Why Did Robinhood Stock Fall?
- Safe Haven Or Just Another Trade? The New Reality For Gold And Silver
- Should You Buy CrowdStrike Stock After Its Recent Pullback?
- BMNR Stock At $23: Buy Ethereum At A Discount?
- Earn 9.4% Today or Buy CROX 40% Cheaper – It’s a Win-Win
- Triggers That Could Ignite the Next Rally In Applied Materials Stock
Playbook On Market Open
The key will be whether the market views the strong guidance as conservative and achievable, setting the stage for future beats. Watch for analyst commentary and upgrades.
- BULL CASE (Gap & Go): The stock needs to hold the initial pre-market highs and see positive analyst revisions to fuel a breakout towards all-time highs.
- BEAR CASE (Gap & Fade): If the market focuses on potential integration risks from recent acquisitions or broader market weakness emerges, the stock could fail to hold the gap up.
- Watch for significant institutional volume to confirm the direction of the initial move.
Verdict
BUY THE OPEN: If the price can consolidate and hold above the $93.50 level, which is near the recent all-time high, we will have a bullish bias for the first 30 minutes. A break below this level suggests the initial pop may fade.
Understanding price behavior can give you and edge. See more.
Want to make sure you never miss the explainer on GMED’s next move? Stay updated with Upcoming Events and Latest Analyses
That’s for now, but so much more goes into evaluating a stock from long-term investment perspective. We make it easy with our Investment Highlights
Stock Picking Falls Short Against Multi Asset Portfolios
Stocks soar and sink but bonds commodities and other assets balance the ride. A multi asset portfolio keeps returns steadier and reduces single market risk.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices